We are advancing innovation in healthcare developments with another pioneering partnership!

We are delighted and proud to announce that GCP-Service International and CRUINT GLOBAL Consulting officially formed a partnership in Prague at the end of March. Currently, GCP-Service is headquartered in Germany, while our company, CRU GLOBAL, operates Phase I trial units in Hungary, Vietnam, and Ukraine, with our headquarters currently located in Singapore. In light […]

CRU Global Network Expands Reach Across CEE and South-East Asian Regions

Global Network Expands

We are excited to share the latest milestone in the CRU Global Network’s journey of expansion and impact in clinical research. In a strategic move, CRU has significantly extended its presence through the establishment of new sites and offices in key locations within the Central and Eastern European (CEE) region, including Poland, the Czech Republic, […]

CRU Global Network Expands Presence in Hungary with Three Specialized Phase I Units

Global Network Expands Presence in Hungary

Exciting news for the CRU community! We are thrilled to announce that CRU Global Network is set to establish three new, highly specialized Phase I units in Hungary during Q1 2024. This expansion marks a significant stride in our commitment to advancing clinical research and bringing cutting-edge solutions to the forefront. The upcoming Phase I […]

CRU Hungary Excels in Early Phase Oncology Studies for Solid Tumors

Early Phase Oncology Studies

As highlighted by industry sources, the competition for sites and resources in oncology research is intense, driven by the rapid growth of oncology drugs in development. CRU Hungary stands as a reliable solution to enrollment challenges, offering expertise and efficiency in the increasingly complex landscape of oncology trials. In the dynamic landscape of early phase […]

Mandatory use of CTIS from 31 January 2023 for all new clinical trial applications

On 31 January 2023, the use of the Clinical Trials Information System (CTIS) will become mandatory for new clinical trial applications and will serve as the single-entry point for submission by sponsors and for regulatory assessment. This follows one year of transition, during which sponsors could choose whether to submit a new clinical trial application […]